# VYTONE- hydrocortisone acetate, iodoquinol cream Eckson Labs LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

-----

Vytone Cream with Aloe (hydrocortisone acetate, USP 1.9%, iodoquinol, USP 1%)

**Rx Only** 

#### **DESCRIPTION:**

Each gram contains 19 mg of hydrocortisone acetate and 10 mg iodoquinol in a vehicle consisting of: aloe vera powder, amino methylpropanol 95%, benzyl alcohol, carbomer, citric acid anhydrous, D&C yellow #10, FD&C blue #1, glycerin, glyceryl polymethacrylate, magnesium aluminum silicate, palmitoyl oligopeptide, PPG-20 methyl glucose ether, propylene glycol, purified water and SD Alcohol 40B.

Hydrocortisone acetate is an anti-inflammatory and antipruritic agent. Chemically, hydrocortisone acetate is [Pregn-4-ene-3, 20-dione, 21-(acetyloxy)-11, 17-dihydroxy-, (11- $\beta$ )-] with the molecular formula (C  $_{23}$ H  $_{32}$ O  $_{6}$ ) and is represented by the following structural formula:

Iodoquinol is an antifungal and antibacterial agent. Chemically, Iodoquinol is [5,7-diiodo-8-quinolinol] with the molecular formula (C  $_9$ H  $_5$ I  $_2$ NO) and is represented by the following structural formula:

#### **CLINICAL PHARMACOLOGY:**

Hydrocortisone acetate has anti-inflammatory, antipruritic and vasoconstrictive properties. While the mechanism of anti-inflammatory activity is unclear, there is evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in humans. Iodoquinol has both antifungal and antibacterial properties.

Pharmacokinetics: The extent of percutaneous absorption of vehicle, the integrity of

the epidermal barrier and the use of occlusive dressings. Hydrocortisone acetate can be absorbed from normal intact skin. Inflammation and/or other inflammatory disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Once absorbed through the skin, hydrocortisone acetate is metabolized in the liver and most body tissue to hydrogenated and degraded forms such as tetrahydrocortisone and tetrahydrocortisol. These are excreted in the urine, mainly conjugated as glucuronides, together with a very small proportion of unchanged hydrocortisone acetate. There are no data available regarding the percutaneous absorption of iodoquinol; however, following oral administration, 3-5% of the dose was recovered in the urine as a glucuronide.

#### INDICATIONS:

Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: "Possibly" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation.

## **CONTRAINDICATIONS:**

This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.

WARNINGS: KEEP OUT OF REACH OF CHILDREN.

PRECAUTIONS: FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

Avoid contact with eyes, lips and mucous membranes.

**Information for Patients:** If irritation develops, the use of this product should be discontinued and appropriate therapy instituted. Staining of the skin, hair and fabrics may occur. Not intended for use on infants or under diapers or occlusive dressings. If extensive areas are treated or if the occlusive dressing technique is used, the possibility exists of increased systemic absorption of the corticosteroid, and suitable precautions should be taken. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

Iodoquinol may be absorbed through the skin and interfere with thyroid function tests. If such tests are contemplated, wait at least one month after discontinuance of therapy to perform these tests. The ferric chloride test for phenylketonuria (PKU) can yield a

false positive result if iodoquinol is present in the diaper or urine. Prolonged use may result in overgrowth of non-susceptible organisms requiring appropriate therapy.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on this product to date. In vitro studies to determine mutagenicity with hydrocortisone have revealed negative results. Mutagenicity studies have not been performed with iodoquinol.

**Pregnancy:** Category C. Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.

**Pediatric Use:** Safety and effectiveness in pediatric patients under the age of 12 have not been established.

#### **ADVERSE REACTIONS:**

The following local adverse reactions are reported infrequently with topical corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, striae and miliaria.

#### DOSAGE AND ADMINISTRATION:

Apply to affected area(s) three to four times per day or as directed by a physician.

#### STORAGE:

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (between 59°F to 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized.

**NOTICE:** Protect from freezing and excessive heat.

#### **HOW SUPPLIED:**

This product is supplied in the following size(s):

Carton, **NDC** 44118-704-30, containing 30 sachets (Net Wt. 2 g each). Each sachet is a unit of use - not for individual sale. Discard sachet after opening.

**To report** a serious adverse event or obtain product information, call 1-855-899-4237.

Manufactured for:

## **Eckson Labs, LLC**

Wilmington, DE 19801 2100546 [00] Rev. 08/2021

BESENDING and your contracts the right hypotocytics oction and 10 mg of hypotocytics and section and 10 mg of hypotocytics and section and 10 mg of hypotocytics and section produced as well previous, ALC (piles with professor, ALC (piles

toloxyg procurat normals:

| Comparison | Co

CLINICAL PHARMACOLOGY: Hydrocordisone notate has anti-infarmatory, antiquatile and vasoconstrictive properties while the mortalism of anti-infarmatory activity is unclear, there is evidence to support that a recognization constitution custs between seasoconstrictive prefer and thereports evidence in numera. Sociational has both armittings and artifacturing properties.

minacional properties.

\*harmacokinetics: The extent of percutaneous absorption

relical standar is determined by come factors including the

vertica, the integrity of the applicant barrier and this use of the counter centrally, informations address on a sharphord counter centrally, informations address on a sharphord counter central cent

does not soovered in the urine as a plusuranticle.

MINICATIONS: Steep a network of a related drug by the habitual beasenth Council and subsequent TAA disselfaction. It is not to the control and subsequent TAA disselfaction. It is not to the control and subsequent TAA disselfaction. It is not to the control and the control and to the control and the co

ingredients of the product.

WARHINGS: KEEP OUT OF REACH OF CHILDREN.

PRECAUTIONS: FOR EXTERNAL USE ONLY. NOT FOR
OPHTHALMIC USE. Avoid contact with eyes, lips and muco
membranes.

nembranes. continued on side panel) (continuate non-back passes) information for events, the use of this product about the occordinated and approximate therapy institutes. Stanling of the about the occordinated and approximate therapy institutes. Stanling of the displacement occurred windows; if externitive season are headed or if the occurred externition is used, this populatility season of conseased systems aboutprine of the orticolations, or another presentant standing or operating and the orticolations; and making reseasons about the orticolations; and stanling reseasons about operating patients and that be more susceptible to systems obtained; and orticolation are obtained to accord to the occurred orticolations and that be more susceptible to systems; tooldly, Passent opticing patient and but be more susceptible to systems; tooldly, Passent opticing research or according to the occurred of the occurred or according to the occurred of the occu

function tests. It such tests are contemptated, wait at least one month after discontinuous or therapy to perform these lests. The terric chloride test for phenyfestrourus (PKU) can yield a take positive result if indequent is present in the disper or unine, Perclangdius ere in yeast, in overgrown of non-succeptible organisms requiring appropriate therapy.

Continuor person, Mulbaneresia and tereatment of Entitlibri I one-form

product to date in vitro studies to determine mutagenicity with hydrocordisone have revealed negative results. Mutagenicity studies have not been performed with lodoquinol. Pregnancy: Cargopy C. Animal reproduction studies have not been conducted with this product. It is also not known whether this product can

Il clashy resource when pounted contents successing potential inscension the first a.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are secreted in human milk, caution should exercised when this product it administered to a nursing woman. (hydrocortisone acetate, USP 1.9%, iodoquinol, USP 1%)
with aloe

30 sachets (Net Wt. 2 g each)

ECKSON LABS

NDC 44118-704-30

Conly Pediatric Use: Safety and e age of 12 have not been est ADVERSE REACTIONS: The reported infrequently with it listed in an approximate des

Agree 1: Invariant contractions and applications are properlied infrarquently with lepical confidencies. These reactions are reported infrarquently with lepical confidencies. These reactions are lated in an approximate decreasing order of occurrence burning, chicking, intration, dyness, folloculatis, hypertrichesis, scendism eruptions, hypophymetrion, portional dormattis, alongle contact dormattis, maceration of the skin, secondary infections, skin atrophy,

ruptions, hyposymentation, perioral dormattis, allergie contact emattis, maceration of the skin, secondary infections, skin atrophy, trise and militaris.

OSAGE AND ADMINISTRATION: Apply to affected area(s) three to use those next over as directed by a obsession.

kinetic temperature does not exceed 25°C (77°F), however, such exposure should be minimized. NOTICE: Protect from freezing and excessive heat. HOW SUPPLIED: This product is supplied in the following size(s):

Carlon, NDC 4418-704-30, containing 30 secrets (Not WL 2 gleac Each sachet is a unit of use - not for individual sale. Discard sachet after opening.

To report a particus adverse award or obtain product information, call

port a serious adverse event or obtain product informations 5-899-4237.

Manufactured for: Eckson Labs, LLC Wilmington, DE 19801

# **VYTONE**

hydrocortisone acetate, iodoquinol cream

## **Product Information**

Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:44118-704

Route of Administration TOPICAL

# **Active Ingredient/Active Moiety**

Ingredient Name

Basis of Strength

HYDROCORTISONE ACETATE (UNII: 3X7931P074) (HYDROCORTISONE UNII:W4X0X7BPJ)

HYDROCORTISONE
ACETATE

HYDROCORTISONE
ACETATE

19 mg
in 1 g

IODOQUINOL (UNII: 63W7IE88K8) (IODOQUINOL - UNII:63W7IE88K8)

IODOQUINOL

10 mg in 1 g

# **Product Characteristics**

Color green Score
Shape Size
Flavor Imprint Code

## **Packaging**

#	tem Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:44118-704- 30	30 in 1 CARTON	03/30/2022	
1	NDC:44118-704- 01	2 g in 1 PACKET; Type 0: Not a Combination Product		

# **Marketing Information**

MarketingApplication Number or MonographMarketing StartMarketing EndCategoryCitationDateDate

unapproved drug other	03/30/2022	

# Labeler - Eckson Labs LLC (078435242)

Revised: 3/2022 Eckson Labs LLC